NCT07093086View on ClinicalTrials.gov

Clinical Study of Multi-targeted CAR-T Therapy in Patients With Relapsed/Refractory B-Cell Lymphoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

November 7, 2024

Primary Completion Date

December 18, 2026

Study Completion Date

December 18, 2028

Conditions
B-cell Lymphoma
Interventions
DRUG

Triple-targeted CAR-T Therapy

Lymphodepletion preconditioning is required prior to CAR-T cell therapy. Lymphodepletion will be performed using a regimen of cyclophosphamide (250-500 mg/m²) and fludarabine (25-30 mg/m²), each administered for 3 consecutive days.

Trial Locations (2)

Unknown

RECRUITING

Hebei Yanda Ludaopei Hospital, Hebei

RECRUITING

Tongji Hospital of Tongji University, Shanghai

All Listed Sponsors
lead

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

INDUSTRY